Results with PCSK9 inhibitor in ODYSSEY OUTCOMES above expectations, mortality benefit included

ACC 2018 Besides the expected effect on prevention of MI, alirocumab was also associated with a decrease of total mortality. In addition, the results give insight in the group of patients that will benefit the most from this drug.

Educational information

This 3-minute education provides a summary of just presented scientific data, recorded during the ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.

Faculty

Prof. Wouter Jukema - cardiologist, Leiden University Medical Center, Leiden, The Netherlands

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Read more about the results of the ODYSSEY OUTCOMES trial